Presentations & Interviews

    Noxopharm 2023 AGM Corporate Presentation  
    Noxopharm talks partnership with Hudson Institute of Medical Research  
    Noxopharm hails new Sofra™ drug inflammation results  
    Noxopharm 2022 AGM Corporate Presentation  
    Ausbiz interview regarding pancreatic cancer research  
    Noxopharm reveals encouraging new pancreatic cancer preclinical study data  
    Noxopharm New Corporate Presentation June 2022  
    Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA  
    Noxopharm Presents at HC Wainright BioConnect Conference 10-13 January 2022  
    Noxopharm Discusses the Subsidiary Pharmorage  
    Noxopharm 2021 AGM Corporate Presentation  
    Noxopharm Updated Corporate Presentation  
    Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears  
    Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results  
    Presentation at Proactive Investors Life Sciences Webinar 10 August 2021  
    Noxopharm Presents at Broker Briefing 1 July 2021  
    Noxopharm Presents at the Stockhead V-CON Biotech virtual event  
    Noxopharm Corporate Presentation  
    Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy  
    CEO Dr Graham Kelly speaks with The Inside Network  
    Interview with Proactive Investors: Noxopharm CEO encouraged by positive interim data from NOXCOVID trial  
    Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021  
    Corporate Presentation for Switzer Virtual Investor Day  
    The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer  
    Noxopharm Presents to the ASX Small & Mid Cap Conference March 2021  
    Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021  

Noxopharm with Proactive at the ASX Small and Mid-Cap Conference (

    ASX Small-Mid Cap Conference Corporate Presentation  
    Noxopharm Presents to H.C. Wainwright Global Conference  
    Noxopharm Updated Corporate Presentation February-March 2021  
    Noxopharm study finds its drug improves prostate cancer survival rates  
    Noxopharm (ASX:NOX) - Hidden Gems Webinar Presentation - ShareCafe  
    Noxopharm To Present to ShareCafe Hidden Gems Webinar  
    Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.  
    Noxopharm Corporate Presentation December Investor Webinar  
    The Market Herald Deal Room Interview with Noxopharm CEO and Managing Director Dr Graham Kelly  
    Switzer Small & Micro Cap Virtual Investor Day 2020  
    Noxopharm 2020 AGM Corporate Update  
    CEO Dr Graham Kelly discusses the announcement of independent validation of Noxopharm's DARRT cancer therapy with TCN TV  
    Noxopharm CMO discusses first patient treated in NOXCOVID trial  
    Noxopharm Corporate Presentation September 2020  
    Pitt Street Research Noxopharm CEO interview August 2020  
    Noxopharm August 2020 EGM Corporate Presentation  
    FNN interview: Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours  
    Reach Markets "Meet the CEO's" Virtual Event July 8, 2020 Recording  
    Corporate Presentation for the Reach Markets Virtual Event  
    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
    Updated Noxopharm Virtual Roadshow Corporate Presentation  
    Noxopharm Virtual Roadshow Corporate Presentation  
    Veyonda® Mode of Action  
    Noxopharm Corporate Presentation February 2020  
    Noxopharm (ASX:NOX) LuPIN trial in prostate cancer  
    Noxopharm Non-Deal Roadshow Presentation  
    Veyonda® - Boosting the effectiveness of radiotherapy  
    DARRT-1 Clinical Data Webinar  
    NOXOPHARM DARRT-1 Interview Dec 2, 2019  
    NOX 2019 AGM webcast  
    Noxopharm 2019 AGM Corporate Presentations  
    NOX and Nyrada TechKnow Invest Roadshow Presentations  
    Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial  
    NOX EGM Chairman's Address and Presentation  
    CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results  
    Noxopharm (ASX:NOX) 3-year listing anniversary update  
    Noxopharm August 2019 Corporate Presentation  
    Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA  
    Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.  
    Noxopharm Corporate Presentation June 2019  
    Switzer Daily: How a biotech company could change cancer treatment  
    CEO Interview DARRT Program 6-month Interim Results  
    Noxopharm Ausbiotech Asia Series March 2019 Presentation  
    March 2019 Corporate Presentation  
    FNN - Shaw & Partners Investor Event 26.2.19  
    St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study  
    FNN interview with Nox Chief Medical Officer on Interim Data  
    2018 Annual General Meeting podcast  
    NOX 2018 AGM Presentations  
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
    NOX Corporate Presentation FNN-Shaw&Partners Investor Event  
    Noxopharm Corporate Presentation for Public Briefing  
    Noxopharm CEO Interview Updates the Company's Current Research and Development Program  
    Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1  
    Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs  
    Corporate Presentation - Post Interim Clinical Data Release  
    Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7  
    NOX Open Briefing Corporate Presentation  
    Noxopharm Limited 2017 AGM Webcast, November 27, 2017  
    AGM Presentations  
    EGM Presentations  
    October 2017 Open Briefing Corporate Presentation  
    Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21  
    New Corporate Presentation  
    New Corporate Presentation  
    Discovery of Idronoxil-C - NOX CEO explains  
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
    ASX The CEO Sessions - ASX Interview  
    ASX The CEO Sessions February 2017 Presentation  
    ASX CEO Presentation Feb 2017 slides  
    Upcoming Events and Presentations  
    Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’  
    November 2016 Corporate Presentation  
    Corporate Presentation Providing Clinical Program Guidance  
    Corporate Presentation  
    Investor Roadshow Presentation